The Healthcare Continuum has seen a realignment that will create a new department, with a new COO role to lead it
Lonza has announced an internal realignment of its business structure to accelerate growth along the Healthcare Continuum and strengthen the Microbial Control business. As part of the change, a new Pharma Biotech & Nutrition (LPBN) segment has been formed.
The company will now have two segments spanning the Healthcare Continuum. One already established division dedicated to Lonza Specialty Ingredients (LSI) that will retain Consumer & Resources Protection and Consumer Product Ingredients. The second segment is the new LPBN division, combining Pharma & Biotech and Consumer Health & Nutrition.
Due to a newly created role from this realignment, Stefan Stoffel has been appointed to the Executive Committee, as COO of LPBN, responsible for operations, from 1 March.
In his position in the new department, Stoffel will cover Operations, Quality, Engineering and Strategic Growth Initiatives across the LPBN segment. Stoffel has been with Lonza since 1991 and has been instrumental in setting up a number of strategic projects, including IbexTM.
Stoffel will join Marc Funk (incoming CEO), Sven Abend (COO LSI) and Rodolfo Savitzky (CFO) on the Executive Committee. The commercial functions of the new LPBN segment will be driven by Marc Funk for the time being.
Lonza states that the realignment will enable both segments to focus on operational excellence, including an integrated global asset strategy that enables a more-cohesive supply chain and asset utilisation.
For the LSI segment, synergies across R&D and commercial functions will open up new market opportunities for the Microbial Control business and enable faster innovation.
In the LPBN segment, translation of technology and know-how from pharma to nutrition, including regulatory and scientific expertise, will strengthen Lonza’s offering.
Commenting on the announcement, Incoming Group CEO Marc Funk, said: “Our new structure will nurture synergies and increase operational efficiency, which will create customer benefits. More importantly, it will enable Lonza to develop a more compelling offer across pharma, biotech and nutrition and to extend our competitive advantage in the market. Stefan is a well-regarded, long-established and strong leader in the Lonza business. His oversight of LPBN segment operations will help us to galvanise our offering and capitalise on future opportunities.”
All future financial reporting will be based on the two new segments Lonza Pharma Biotech & Nutrition (LPBN) and Lonza Specialty Ingredients (LSI).